![William Moore](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
William Moore
Amministratore Delegato presso Propella Therapeutics, Inc.
Posizioni attive di William Moore
Società | Posizione | Inizio | Fine |
---|---|---|---|
Propella Therapeutics, Inc.
![]() Propella Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Propella Therapeutics, Inc. is an American biopharmaceutical company that has developed a platform combining medicinal chemistry with lymphatic targeting to create best- or first-in-class oncology drugs that have validated MOAs and biological targets but suffer from efficacy and safety limitations. Propella is based in an undisclosed location and is dedicated to meeting the needs of cancer patients currently underserved by existing standards of care. The company is currently in the phase 1 portion of a phase 1/2a study of its lead product candidate, PRL-02, for the treatment of metastatic prostate cancer. The company was founded by William E. Peterson, Charles Birbara, Milt V. Peterson, and the CEO is William Moore. | Direttore/Membro del Consiglio | 01/01/2017 | - |
Amministratore Delegato | 01/01/2017 | - | |
Presidente | 01/01/2017 | - |
Storia della carriera di William Moore
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Posizioni
Director/Board Member | 1 |
Chief Executive Officer | 1 |
President | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Propella Therapeutics, Inc.
![]() Propella Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Propella Therapeutics, Inc. is an American biopharmaceutical company that has developed a platform combining medicinal chemistry with lymphatic targeting to create best- or first-in-class oncology drugs that have validated MOAs and biological targets but suffer from efficacy and safety limitations. Propella is based in an undisclosed location and is dedicated to meeting the needs of cancer patients currently underserved by existing standards of care. The company is currently in the phase 1 portion of a phase 1/2a study of its lead product candidate, PRL-02, for the treatment of metastatic prostate cancer. The company was founded by William E. Peterson, Charles Birbara, Milt V. Peterson, and the CEO is William Moore. | Health Technology |
- Borsa valori
- Insiders
- William Moore
- Esperienza